ClinicalTrials.govpublic full text
Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)
ovarian cancer, antineoplastic agent, fragmin, dalteparin, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 829682
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.